CN104136023A - 降低心血管疾病风险的方法 - Google Patents

降低心血管疾病风险的方法 Download PDF

Info

Publication number
CN104136023A
CN104136023A CN201380004642.2A CN201380004642A CN104136023A CN 104136023 A CN104136023 A CN 104136023A CN 201380004642 A CN201380004642 A CN 201380004642A CN 104136023 A CN104136023 A CN 104136023A
Authority
CN
China
Prior art keywords
patient
ldl
compound
formula
statins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380004642.2A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·L·比斯盖尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yao Shi Treatment Co
Original Assignee
Gemphire Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics LLC filed Critical Gemphire Therapeutics LLC
Priority to CN201910123564.7A priority Critical patent/CN110025608A/zh
Publication of CN104136023A publication Critical patent/CN104136023A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380004642.2A 2012-01-06 2013-01-04 降低心血管疾病风险的方法 Pending CN104136023A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910123564.7A CN110025608A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584002P 2012-01-06 2012-01-06
US61/584,002 2012-01-06
PCT/US2013/020317 WO2013103842A1 (en) 2012-01-06 2013-01-04 Methods of reducing risk of cardiovascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910123564.7A Division CN110025608A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法

Publications (1)

Publication Number Publication Date
CN104136023A true CN104136023A (zh) 2014-11-05

Family

ID=48745439

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380004642.2A Pending CN104136023A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法
CN201910123564.7A Pending CN110025608A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910123564.7A Pending CN110025608A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法

Country Status (9)

Country Link
US (2) US10028926B2 (enExample)
EP (2) EP2800564B1 (enExample)
JP (2) JP6295205B2 (enExample)
CN (2) CN104136023A (enExample)
AU (1) AU2013207423B2 (enExample)
CA (1) CA2861643C (enExample)
HK (1) HK1201452A1 (enExample)
MX (1) MX367352B (enExample)
WO (1) WO2013103842A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348491A (zh) * 2015-11-06 2018-07-31 燿石治疗公司 治疗混合性血脂异常
CN108697677A (zh) * 2016-02-26 2018-10-23 燿石治疗公司 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9440754B2 (en) 2012-03-29 2016-09-13 R.P. Scherer Technologies, Llc Three circuit fill system for blow fill seal containers
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2909442A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN111704543A (zh) 2014-11-14 2020-09-25 燿石治疗公司 用于制备α,ω-二羧酸封端的二烷醚的方法和中间体
SG11201707497UA (en) 2015-03-13 2017-10-30 Esperion Therapeutics Inc Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3579827A4 (en) * 2017-02-08 2021-01-06 Esperion Therapeutics, Inc. FORMULATIONS OF ASSOCIATIONS OF THREE ACTIVE INGREDIENTS AND METHODS OF TREATMENT OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
US20180297929A1 (en) * 2017-04-18 2018-10-18 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
US20190008779A1 (en) * 2017-05-11 2019-01-10 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
EP3986860A1 (en) 2019-06-21 2022-04-27 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1999030704A1 (en) * 1997-12-12 1999-06-24 Warner-Lambert Company Statin-carboxyalkylether combinations
US20090312355A1 (en) * 2006-08-03 2009-12-17 Trustees Of Tufts College Non-Flushing Niacin Analogues, and Methods of Use Thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
ATE384035T1 (de) 1999-04-01 2008-02-15 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
EP1351916A2 (en) 2000-10-11 2003-10-15 Esperion Therapeutics Inc. Ether compounds and compositions for cholesterol management and related uses
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
WO2007067817A1 (en) 2005-12-07 2007-06-14 Cv Therapeutics, Inc. Abca1 elevating compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1999030704A1 (en) * 1997-12-12 1999-06-24 Warner-Lambert Company Statin-carboxyalkylether combinations
US20090312355A1 (en) * 2006-08-03 2009-12-17 Trustees Of Tufts College Non-Flushing Niacin Analogues, and Methods of Use Thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348491A (zh) * 2015-11-06 2018-07-31 燿石治疗公司 治疗混合性血脂异常
CN108366957A (zh) * 2015-11-06 2018-08-03 燿石治疗公司 用于治疗心血管疾病的吉卡宾组合
CN108697677A (zh) * 2016-02-26 2018-10-23 燿石治疗公司 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途

Also Published As

Publication number Publication date
JP2018104452A (ja) 2018-07-05
MX2014008180A (es) 2014-10-14
HK1201452A1 (en) 2015-09-04
US20150005386A1 (en) 2015-01-01
WO2013103842A1 (en) 2013-07-11
JP6295205B2 (ja) 2018-03-14
US20180303779A1 (en) 2018-10-25
EP3735967A1 (en) 2020-11-11
CA2861643A1 (en) 2013-07-11
CA2861643C (en) 2020-10-06
EP2800564A1 (en) 2014-11-12
US10709678B2 (en) 2020-07-14
JP2015503588A (ja) 2015-02-02
AU2013207423B2 (en) 2017-10-12
MX367352B (es) 2019-08-16
EP2800564B1 (en) 2020-05-06
CN110025608A (zh) 2019-07-19
EP2800564A4 (en) 2015-07-22
AU2013207423A1 (en) 2014-07-24
US10028926B2 (en) 2018-07-24

Similar Documents

Publication Publication Date Title
CN104136023A (zh) 降低心血管疾病风险的方法
US20240148681A1 (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
US20180064671A1 (en) Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease
JP2009540003A (ja) Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
US20210290580A1 (en) New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
HK1250484A1 (zh) 用於治疗胰腺炎的吉卡宾和衍生物
HK40007806A (en) Methods of reducing risk of cardiovascular disease
JP2014509305A5 (enExample)
CN110013474A (zh) 非诺贝特的新用途以及针对新用途的药物
CN102416015A (zh) 一种含他汀类药物的组合物及其用途
JPWO2003099332A1 (ja) Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用
CN111743869A (zh) 一种匹伐他汀钙片剂及其制备方法
JP2007508242A (ja) トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: YAOSHI THERAPY COMPANY

Free format text: FORMER OWNER: MICHIGAN LIFE THERAPEUTICS LLC

Effective date: 20150127

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150127

Address after: michigan

Applicant after: Yao Shi treatment company

Address before: Michigan

Applicant before: Michigan Life Therapeutics, LLC

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201452

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141105

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201452

Country of ref document: HK